Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 3, 2011, Pages 379-387

  Bhorade, Sangeeta ^a   Ahya, Vivek N ^b   Baz, Maher A ^c   Valentine, Vincent G ^d   Arcasoy, Selim M ^e   Love, Robert B ^f   Seethamraju, Harish ^g   Alex, Charles G ^f   Bag, Remzi ^h   DeOliveira, Nilto C ⁱ   Husain, Aliya ^a   Vigneswaran, Wickii T ^a,b   Charbeneau, Jeff ^a   Krishnan, Jerry A ^a   Durazo Arvizu, Ramon ^f   Norwick, Lourdes ^a   Garrity, Edward ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h INTEGRIS BAPTIST MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Lung transplantation; Sirolimus; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; DACLIZUMAB; GANCICLOVIR; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BLEEDING; BRONCHUS STENOSIS; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LEUKOPENIA; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEOPLASM; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSBRONCHIAL BIOPSY;

AZATHIOPRINE; BRONCHIOLITIS OBLITERANS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS; TIME FACTORS;

EID: 79551533169     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201005-0775OC     Document Type: Article

References (41)

1. Christie J, Edwards LM, Aurora P, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Taylor DO, Kucheryavaya AY, Hertz MI. The registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult lung and heart lung transplantation report - 2009. J Heart Lung Transplant 2009;28:1031-1049.
2. Estenne M, Hertz M. Bronchiolitis obliterans after human lung transplant. Am J Respir Crit Care Med 2002;166:440-444.
3. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ, et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4-13.
4. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114:195-202.
5. Girgis RE, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, Ting A, Johnstone I, Miller J, Robbins RC, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996;15:1200-1208.
6. Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998;17:1255-1263.
7. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999;159:829-833.
8. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002;21:271-281.
9. Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, Glanville A, Gould FK, Magro C, Marboe CC, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007;26:1229-1242.
10. Palmer SM, Baz MA, Sanders L, Miralles AP, Lawrence CM, Rea JB, Zander DS, Edwards LJ, Staples ED, Tapson VF, Davis RD. Results of a randomized prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001;71:1772-1776.
11. McNeil K, Glanville AR, Wahlers T, Knoop C, Speich R, Mamelok RD, Maurer J, Ives J, Corris PA. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006;81:998-1003.
12. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008;14:633-638.
13. Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006;20:30-43.
14. Vigano M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: a 24 month analysis. J Heart Lung Transplant 2007;26:584-592.
15. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantinevon Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003;349:847-858.
16. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35(3, Suppl):7S-14S.
17. Sehgal SN. Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-340.
18. King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003;75:1437-1443.
19. Bhorade SM, Baz MA, Ahya V, Seethamraju H, Valentine V, Arcasoy S, Love R, Alex C, Vigneswaran WT, Krishnan J, et al. Comparison of a tacrolimus/sirolimus/prednisone regimen versus tacrolimus/azathioprine/ prednisone immunosuppressive regimen in lung transplantation [abstract]. J Heart Lung Transplant 2008;27:S207.
20. Bhorade SM, Ahya V, Kotloff R, Baz M, Valentine V, Arcasoy S, Love R, deOliveira R, Bag R, Seethamraju H, et al. Long term follow-up in the AIRSAC trial, a multicenter randomized clinical trial in lung transplant recipients [abstract]. J Heart Lung Transplant 2009;28:S119-S120.
21. National Cholesterol Education Program (NCEP) Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
22. Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Husain AN, Hruban RH, Marchevsky A, Ohori NP, Ritter J, Stewart S, Tazelaar HD. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996;15:1-15.
23. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297-310.
24. Humar A. Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6:262-274.
25. Cahill BC, Somerville KT, Cromptom JA, Parker ST, O'Rourke MK, Stringham JC, Karwande SV. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003;22:169-176.
26. Lischke R, Simonek J, Matousovic K, Stolz AJ, Schützner J, Vojácek J, Burkert J, Davidová R, Pafko P. Initial single center experience with sirolimus after lung transplantation. Transplant Proc 2006;38:3006-3011.
27. Groetzner J, Wittwer T, Kaczmarek I, Ueberfuhr P, Strauch J, Nagib R, Meiser B, Franke U, Reichart B, Wahlers T. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006;81:355-360.
28. Villanueva J, Boukhamseen A, Bhorade SM. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J Heart Lung Transplant 2005;24:421-425.
29. Ussetti P, Laporta R, de Pablo A, Carreño C, Segovia J, Pulpón L. Rapamycin in lung transplantation: preliminary results. Transplant Proc 2003;35:1974-1977.
30. Snell GI, Valentine VG, Vitulo P, Glanville AR, McGiffin DC, Loyd JE, Roman A, Aris R, Sole A, Hmissi A, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006;6:169-177.
31. Hachem RR, Yusen RD, Chakinala MM, Meyers BF, Lynch JP, Aloush AA, Patterson GA, Trulock EP. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007;26:1012-1018.
32. Vigano M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF; RAD A2411 Study Investigators. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized multicenter study. Transpl Infect Dis 2009;12:23-30.
33. Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007;84:1436-1442.
34. Ozaki KS, Camara NOS, Galante NZ, Camargo LF, Pacheco-Silva A. Decreased cytomegalovirus infection after antilymphocyte therapy in sirolimus treated renal transplantations. Int Immunopharmacol 2005;5:103-106.
35. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234-1248.
36. Johnson RA, Wang X, Ma XL, Huong SM, Huang ES. Human cytomegalovirus upregulates the phosphatidylinositol 3 kinase (PI3- K) pathway: inhibition of PI3-K activity inhibits viral replication and viral induced signaling. J Virol 2001;75:6022-6032.
37. Eisenreich A, Celebi O, Goldin-Lang P, Schultheiss HP, Rauch U. Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel. Int Immunopharmacol 2008;8:307-311.
38. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058.
39. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF, Tanner FC. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005;112:2002-2011.
40. Muldowney JA III, Stringham JR, Levy SE, Gleaves LA, Eren M, Piana RN, Vaughan DE. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 2007;27:400-406.
41. U.S. Food and Drug Administration. Rapamune (sirolimus) April 2002. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm154514.htm.